KCNK17 encodes TASK-4, a two-pore-domain potassium channel that conducts voltage-dependent outward rectifying currents through an 'ion flux gating' mechanism where outward potassium flow, but not inward flow, opens the channel gate. The channel forms homo- and heterodimerized complexes with distinct regulatory properties and is expressed in the cardiac conduction system, where it regulates action potential duration and beating frequency. Gain-of-function mutations in KCNK17 have been identified in patients with severe cardiac conduction disorder and idiopathic ventricular fibrillation 1. The G88R mutation increased channel conductivity in a dominant-active manner and slowed action potential upstroke velocity in cardiac myocytes, suggesting that KCNK17 dysfunction compounds sodium channel defects in arrhythmia pathogenesis 1. KCNK17 variants are also associated with cerebral hemorrhage in Chinese populations; the rs10947803 A allele increases hemorrhagic stroke risk, while the rs12214600 T carrier shows reduced risk 2 3. A variant near KCNK17 (rs2815063-A) was associated with cancer therapy-induced cardiac dysfunction in childhood cancer survivors, particularly among those exposed to doxorubicin, with dysregulation of KCNK17 enhancers as the underlying mechanism 4. In hepatocellular carcinoma, KCNK17 downregulation correlates with improved prognosis and has potential diagnostic utility 5. Recent evidence identifies KCNK17 as part of a seven-gene transcriptomic signature predictive of response to TNF inhibitor therapy in rheumatoid arthritis 6.